147 related articles for article (PubMed ID: 22182694)
1. Preliminary study: treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosis.
Kress-Bennett JM; Ehrlich GD; Bruno A; Post JC; Hu FZ; Scott TF
BMC Neurol; 2011 Dec; 11():155. PubMed ID: 22182694
[TBL] [Abstract][Full Text] [Related]
2. LFA-1 expression on CD4(+)CD45RO(+) peripheral blood T-lymphocytes in RR MS: effects induced by rIFNbeta-1a.
Avolio C; Ruggieri M; Cafforio P; Giuliani F; Silvestris F; Dammacco F; Livrea P; Trojano M
J Neurol Sci; 2001 May; 186(1-2):65-73. PubMed ID: 11412874
[TBL] [Abstract][Full Text] [Related]
3. CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis.
Sellebjerg F; Ross C; Koch-Henriksen N; Sørensen PS; Frederiksen JL; Bendtzen K; Sørensen TL
Mult Scler; 2005 Dec; 11(6):641-5. PubMed ID: 16320722
[TBL] [Abstract][Full Text] [Related]
4. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
Khademi M; Wallström E; Andersson M; Piehl F; Di Marco R; Olsson T
J Neuroimmunol; 2000 Mar; 103(2):202-10. PubMed ID: 10696916
[TBL] [Abstract][Full Text] [Related]
5. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
7. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4.
Furlan R; Bergami A; Lang R; Brambilla E; Franciotta D; Martinelli V; Comi G; Panina P; Martino G
J Neuroimmunol; 2000 Nov; 111(1-2):86-92. PubMed ID: 11063825
[TBL] [Abstract][Full Text] [Related]
9. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis.
Salama HH; Kolar OJ; Zang YC; Zhang J
Mult Scler; 2003 Feb; 9(1):28-31. PubMed ID: 12617264
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
[TBL] [Abstract][Full Text] [Related]
11. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment.
Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):123-6. PubMed ID: 12486283
[TBL] [Abstract][Full Text] [Related]
12. Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.
Christophi GP; Christophi JA; Gruber RC; Mihai C; Mejico LJ; Massa PT; Jubelt B
J Neurol Sci; 2011 Aug; 307(1-2):41-5. PubMed ID: 21658727
[TBL] [Abstract][Full Text] [Related]
13. The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.
de Lemos LLP; Guerra Júnior AA; Santos M; Magliano C; Diniz I; Souza K; Pereira RG; Alvares J; Godman B; Bennie M; Zimmermann IR; Dos Santos VCC; Pretramale CA; Acurcio FA
Pharmacoeconomics; 2018 Feb; 36(2):161-173. PubMed ID: 29139001
[TBL] [Abstract][Full Text] [Related]
14. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
[TBL] [Abstract][Full Text] [Related]
15. Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Nischwitz S; Faber H; Sämann PG; Domingues HS; Krishnamoorthy G; Knop M; Müller-Sarnowski F; Yassouridis A; Weber F
Acta Neurol Scand; 2014 Jul; 130(1):46-52. PubMed ID: 24571587
[TBL] [Abstract][Full Text] [Related]
16. Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up.
Milosevic E; Dujmovic I; Markovic M; Mesaros S; Rakocevic G; Drulovic J; Mostarica Stojkovic M; Popadic D
J Neuroimmunol; 2015 Oct; 287():64-70. PubMed ID: 26439963
[TBL] [Abstract][Full Text] [Related]
17. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
18. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.
Bushnell SE; Zhao Z; Stebbins CC; Cadavid D; Buko AM; Whalley ET; Davis JA; Versage EM; Richert JR; Axtell RC; Steinman L; Medori R
Neurology; 2012 Aug; 79(6):531-7. PubMed ID: 22573631
[TBL] [Abstract][Full Text] [Related]
19. Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis.
Guijarro C; Benito-León J; Bermejo-Pareja F
Neurol Sci; 2011 Apr; 32(2):309-11. PubMed ID: 20890624
[TBL] [Abstract][Full Text] [Related]
20. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells.
Sweeney CM; Lonergan R; Basdeo SA; Kinsella K; Dungan LS; Higgins SC; Kelly PJ; Costelloe L; Tubridy N; Mills KH; Fletcher JM
Brain Behav Immun; 2011 Aug; 25(6):1170-81. PubMed ID: 21420486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
